Table 2.
Time-dependent hazard ratios and 95% confidence intervals for sick leave
| Type of treatment | Sick leave | |||||
|---|---|---|---|---|---|---|
| Month 6 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
| HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | |
| Chemotherapy | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.70 (1.49–1.95) | 1.47 (1.34–1.62) | 1.25 (1.17–1.33) | 1.22 (1.14–1.30) | 1.20 (1.13–1.28) | 1.19 (1.11–1.28) |
| Radiotherapy (RT) | ||||||
| Mastectomy only | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Mastectomy + RT | 1.23 (0.99–1.53) | 1.16 (1.00–1.34) | 1.08 (0.98–1.19) | 1.07 (0.98–1.17) | 1.07 (0.97–1.17) | 1.06 (0.96–1.17) |
| BCS + RT | 1.21 (1.02–1.42) | 0.80 (0.71–0.9) | 0.62 (0.57–0.68) | 0.63 (0.58–0.68) | 0.62 (0.57–0.68) | 0.61 (0.56–0.67) |
| Endocrine therapyb | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 0.89 (0.74–1.06) | 1.01 (0.89–1.14) | 1.12 (1.02–1.23) | 1.13 (1.04–1.24) | 1.14 (1.04–1.25) | 1.15 (1.05–1.26) |
ALND axillary lymph node dissection, BCS breast-conserving surgery, ER estrogen receptor, RT radiotherapy, SNB sentinel node biopsy
aHazard ratios were adjusted for chemotherapy, radiotherapy/surgery, endocrine therapy, tumor size, lymph node involvement, axillary lymph node dissection, ER status, age at diagnosis, level of education, prior sick leave, region of residency, and calendar year of diagnosis. The underlying time-scale was time since diagnosis
bInitiation of endocrine therapy